Back

Elevated triglycerides are related to higher residual cardiovascular disease and mortality risk independent of lipid targets and lipid-lowering therapy intensity in cardiovascular disease patients

29 August 2025 (07:00 - 18:00)
Organised by: Logo
Congress Presentation Part of: Lipids (1) Lipids ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Miss Pauline Christine Eleonore Schuitema

University Medical Center Utrecht, Utrecht (Netherlands (The))

7 More presentations in this session

Presentation thumbnail
The effect of baseline low-normal insulin-like growth factor-1 on the relation between lipoprotein (a) and incident type 2 diabetes and outcome: observations from the UK-Biobank.
Doctor J. Sangha (Cambridge, GB)
Abstract Slides Video
Presentation thumbnail
Project on lipid profile optimization in very high cardiovascular risk patients through a virtual lipid unit in our city healthcare area
Doctor L. Villafafila (Toledo, ES)
Abstract Slides Video
Presentation thumbnail
Validation of the familial hypercholesterolemia diagnosis in the Danish National Patient Registry and the Danish familial hypercholesterolemia registry
Doctor J. Knold (Odense, DK)
Abstract Slides Video
Presentation thumbnail
Elevated remnant cholesterol confers high risk of ASCVD without prompting lipid-lowering therapy: an unmet medical need
Doctor K. Hvid (Herlev, DK)
Abstract Slides Video
Presentation thumbnail
Discordance in the measurement of Achilles tendon thickness between soft X-ray radiography and ultrasonography among patients with coronary artery disease
Doctor T. Itagaki (Matsumoto, JP)
Abstract Slides Video

Access the full session

Session thumbnail
Lipids (1)

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025
You may be interested in
thumbnail
Congress Presentation
Effect of triglycerides on cardiovascular risk in patients with a first vs. recurrent acute coronary syndrome
thumbnail
Congress Presentation
Welcome & introduction
thumbnail
Congress Presentation
Icosapent ethyl reduces cardiovascular risk across apolipoprotein b and fasting triglyceride rich lipoprotein levels

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources